ASCO 2018: Science of Oncology Award Lecture: Preventing HPV-Associated Cancers by Vaccination

Chicago, IL (UroToday.com) Douglas Lowy, MD, received the prestigious Science of Oncology Award, followed by his accompanying lecture discussing the prevention of HPV-associated cancers by vaccination. 

Lowy started his presentation by discussing the epidemiology of HPV-associated cancers. He notes that cervical cancer mortality rates will continue to increase in less developed regions of the world, with 251,000 cervical deaths in 2015 expected to reach 363,000 in 2030.

ASCO 2018: Optimizing Systemic Therapy in Advanced Renal Cell Carcinoma

Chicago, IL (UroToday.com) Toni Choueiri, MD, provided a discussion following three Renal Cell Carcinoma (RCC) oral abstracts presented at the 2018 ASCO annual meeting. The first study was results of the KEYNOTE-427 study presented by David F. McDermott, MD. This study evaluated monotherapy pembrolizumab as first-line therapy for patients with mRCC, noting promising antitumor activity for pembrolizumab treating clear cell RCC across IMDC risk groups with an ORR of 38%.

ASCO 2018: Patient-reported Outcomes in IMmotion151: Atezolizumab + Bevacizumab vs Sunitinib in Treatment Naive mRCC

Chicago, IL (UroToday.com) At GU ASCO earlier this year in San Francisco, Robert Motzer, MD, presented the first results of the IMmotion151, a randomized, open-label phase III study assessing atezolizumab + bevacizumab vs sunitinib in treatment naive mRCC patients [1]. IMmotion151 met its co-primary endpoint in PD-L1+ patients with improvement in investigator-assessed progression-free survival (PFS) for patients receiving atezolizumab + bevacizumab compared to sunitinib (HR 0.74, 95%CI 0.57-0.96; median PFS 11.2 vs 7.7 months).

ASCO 2018: Updated Phase 1 Data Announced for Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy

Truckee, CA (UroToday.com) -- Updated Data from Phase 1 EV-101 Study Highlighted in ASCO 2018 Oral Presentation Support Rapid Development Program and Ongoing Pivotal Study Astellas Pharma Inc. and Seattle Genetics, Inc. announced the presentation of updated phase 1 data of enfortumab vedotin, an investigational antibody-drug conjugate (ADC), at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting in Chicago.

ASCO 2018: Abiraterone Acetate and Prednisone, AAP Plus Degarelix, and Degarelix Alone for Patients with Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy

Chiago, IL (UroToday.com) Men with short intervals to PSA failure or fast PSA doubling times after prostatectomy or radiation therapy have increased incidence of distant metastases and prostate specific mortality1,2.   In a cohort of 8,669 men treated with surgery or radiation, men with a PSA doubling time of less than 3 months had a 20 fold increased risk of prostate cancer specific mortality compared with me with a doubling time greater than 3 months3. PSA recurrence has been reported in up to 30% of patients following prostatectomy, most of whom recur in the first five years4. In this setting, combination anti-androgen therapy may have an opportunity to eliminate all disease in a low volume state, potentially providing an opportunity for cure.

ASCO 2018: A phase II Study Investigating the Safety and Efficacy of Neoadjuvant Atezolizumab in Muscle Invasive Bladder Cancer (ABACUS)

Chicago, IL (UroToday.com) Thomas Powles from the UK presented the initial results of the ABACUS phase II trial assessing atezolizumab as neoadjuvant therapy for patients with MIBC and ineligible for cisplatin. Radical cystectomy is the standard of care for bladder cancer patients with cT2-4aN0M0 disease, and neoadjuvant cisplatin-based chemotherapy is routinely given prior to cystectomy based on level 1 data [1-2].

ASCO 2018: Preoperative Pembrolizumab Before Radical Cystectomy for Muscle-Invasive Urothelial Bladder Carcinoma: Interim Clinical and Biomarker Findings from the Phase 2 PURE-01 Study

Chicago, IL (UroToday.com) There is level 1 evidence suggesting a survival benefit among patients that receive cisplatin-based neoadjuvant chemotherapy for muscle-invasive bladder cancer (MIBC) prior to radical cystectomy compared to immediate radical cystectomy [1]. However, for a variety of reasons, neoadjuvant chemotherapy is only administered to a minority of patients (~20%). With the recent reporting of KEYNOTE-045 in 2017 [2], pembrolizumab was associated with significantly longer overall survival (by approximately 3 months) and a lower rate of treatment-related adverse events than chemotherapy as second-line therapy for platinum-refractory bladder cancer. As such, pembrolizumab use in the neoadjuvant setting is intriguing.